详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration

55| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA [2]Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA [3]Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA [4]Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Hubei, Peoples R China [5]Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA [6]Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA [7]Johns Hopkins Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA [8]Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27710 USA [9]Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA

出处：

DOI：

ISSN：

摘要：

UDP-glucose 6-dehydrogenase (UGDH) produces UDP-alpha-D-glucuronic acid, the precursors for glycosaminoglycans (GAGs) and proteoglycans of the extracellular matrix. Elevated GAG formation has been implicated in a variety of human diseases, including glioblastoma (GBM). In our previous study, we found that Kruppel-like factor 4 (KLF4) promotes GBM cell migration by binding to methylated DNA, mainly methylated CpGs (mCpG) and transactivating gene expression. We identified UDGH as one of the downstream targets of KLF4-mCpG binding activity. In this study, we show that KLF4 upregulates UGDH expression in a mCpG-dependent manner, and UGDH is required for KLF4-induced cell migration in vitro. UGDH knockdown decreases GAG abundance in GBM cells, as well as cell proliferation and migration in vitro. In intracranial xenografts, reduced UGDH inhibits tumor growth and migration, accompanied by a decrease in the expression of extracellular matrix proteins such as tenascin C, brevican. Our studies demonstrate a novel DNA methylation-dependent UGDH upregulation by KLF4. Developing UGDH antagonists to decrease the synthesis of extracellular matrix components will be a useful strategy for GBM therapy.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区遗传学 2 区生化与分子生物学 2 区细胞生物学 2 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区生化与分子生物学 1 区遗传学 2 区细胞生物学 2 区肿瘤学

JCR分区：

出版当年[2016]版：

Q1 GENETICS & HEREDITY Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 ONCOLOGY Q1 CELL BIOLOGY

最新[2023]版：

Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 CELL BIOLOGY Q1 GENETICS & HEREDITY Q1 ONCOLOGY

影响因子： 6.9 最新[2023版] 7.5 最新五年平均 7.519 出版当年[2016版] 7.272 出版当年五年平均 7.932 出版前一年[2015版] 6.854 出版后一年[2017版]

第一作者：

第一作者单位： [1]Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA [2]Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA

通讯作者：

通讯机构： [1]Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA [3]Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA

推荐引用方式(GB/T 7714)：

APA：

MLA：